Sex differences in clinical trials of ALRV5XR treatment of androgenetic alopecia and telogen effluvium.

Front Med (Lausanne) · 2022 · PMC9421616 · PMID 36045927

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Growth and shedding rates The growth rate for women treated with ALRV5XR increased by 30.7 μm/24 h ( p = 0.0001) or 10.0% ( p = 0.0001) when compared to placebo, and the men’s increase was borderline significant.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.